The Effect of Epitomee Capsule on Body Weight in Patients With Overweight and Obesity

NCT ID: NCT04222322

Last Updated: 2024-03-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 279 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-15
• Study Completion Date: 2023-12-30

Brief Summary

The effect of Epitomee Capsule on body weight in patients with overweight and obesity with and without Prediabetes

Detailed Description

This is a Prospective, Randomized, Double-blind, Placebo controlled, Multi-center, Pivotal, Adaptive trial designed to demonstrate that the use of Epitomee Capsule, in combination with lifestyle modification, is superior to the placebo device in reducing body weight at 24-weeks

Conditions

Overweight and Obesity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Epitomee Capsule

Epitomee Capsule combined with moderate intensity lifestyle counseling

Group Type: EXPERIMENTAL

Epitomee Capsule

Intervention Type: DEVICE

Arm treatment: Epitomee Capsule combined with moderate intensity lifestyle counseling.

Control-Placebo

Visually matching (to Epitomee capsule) placebo capsule combined with moderate intensity lifestyle counseling

Group Type: PLACEBO_COMPARATOR

Control-Placebo

Intervention Type: OTHER

Arm treatment: Visually matching placebo capsule combined with moderate intensity lifestyle counseling.

Interventions

Epitomee Capsule

Arm treatment: Epitomee Capsule combined with moderate intensity lifestyle counseling.

Intervention Type: DEVICE

Control-Placebo

Arm treatment: Visually matching placebo capsule combined with moderate intensity lifestyle counseling.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Men or women >= 18 years

2. Current BMI of 25.0-40.0 kg/m2 inclusive

3. Eligible female subjects will be:

Non-pregnant, evidenced by a negative urine dipstick pregnancy test Non-lactating Females will be either surgically sterile or postmenopausal or agree to continue using an accepted method of birth control during the study.

4. Normoglycemic subjects with both:

1. Fasting plasma glucose <100 mg/dL

2. HbA1c <5.7% or:

Prediabetic subjects with either one or both of the following criteria:

1. FPG≥100 mg/dL and <126 mg/dL

2. 5.7% ≤ HbA1c ≤6.4% Naive Prediabetes or treated with metformin (up to 2000mg/dL inclusive)

5. Ability to provide informed consent before any trial-related activities

6. Ability and willingness to complete the physical activity in accordance to the study's exercise program

7. Willingness to maintain a diet in accordance with study requirement for the duration of the study

8. Subjects must have:

• A primary care provider who is responsible for providing routine care
• A reliable telephone or internet service to communicate with study staff

9. Understand and be willing to comply with all study-related procedures and agree to participate in the study by giving written informed consent

10. Study subjects must be willing to notify the staff of any change in their medical health (including surgeries) or change in drug treatments (addition of drugs, stopping of drugs, or change in drug dose) during the course of the trial.

11. Previously attempted to lose weight unsuccessfully using a medically supervised or self-directed diet.

12. Willingness to avoid medications or other substances known to affect weight changes during the study

13. Willingness to avoid non-steroidal anti-inflammatory drugs (NSAIDs) other than low dose aspirin including Diclofenac, Ibuprofen, Naproxen, or other medications known to be gastric irritants during the study.

14. Subjects on psychiatric medications are clinically well-controlled with a stable psychiatric medication dose for at least 3 months prior to study entry.

Exclusion Criteria

1. Pregnant or nursing, or plans to become pregnant in the next 12 months, or not using adequate contraceptive measures

2. Weight loss of more than 10 pounds in the past 6 months

3. Use in the past 6 months of medications or other substances known to induce weight gain or weight loss

4. Participation in any clinical study (weight-loss or non-weight loss study) within the past 3 months

5. Known history of endocrine disorders affecting weight, such as uncontrolled abnormal thyroid function, hypothalamic tumors, Cushing's syndrome, or other genetic syndromes

6. Currently receiving chronic steroid or immunosuppressive therapy

7. Subjects previously diagnosed with HIV, hepatitis B or C

8. Subjects diagnosed with bulimia, binge eating disorder, compulsive overeating, high liquid calorie intake, or similar eating related psychological disorders

9. Intent to undergo gastric surgery or gastric banding during the study period or within the 6-month period after completion of this study

10. Prior use of any weight loss gastric medical device such as gastric balloon or gastric aspiration device

11. Known history of structural or functional disorders of the esophagus that may impede passage of the device through the gastrointestinal tract, including: Barrett's esophagus, esophagitis, dysphagia, achalasia, stricture/stenosis, esophageal varices, esophageal diverticula, esophageal perforation, or any other disorder of the esophagus

12. Known history of any swallowing disorder, esophageal chest pain disorders, or drug refractory esophageal reflux symptoms

13. Known history of structural or functional disorders of the stomach including, gastric ulcer, chronic gastritis, gastric varices, hiatal hernia (> 2 cm), cancer or any other disorder of the stomach or any symptoms of chronic upper abdominal pain, chronic nausea, chronic vomiting, chronic dyspepsia or symptoms suggestive of gastroparesis, including post-prandial fullness or pain, post-prandial nausea or vomiting or early satiety.

14. Known history of duodenal ulcer, intestinal diverticula (diverticulitis), intestinal varices, intestinal stricture/stenosis, small bowel obstruction, or any other obstructive disorder of the gastrointestinal (GI) tract

15. Currently have ongoing symptoms suggestive of intermittent small bowel obstruction, such as recurrent bouts of post-prandial abdominal pain, nausea or vomiting

16. Known history of irritable bowel syndrome, radiation enteritis or other inflammatory bowel disease, such as Crohn's disease

17. Known history of GI surgeries that may have resulted in anatomical GI tract abnormalities such as a stoma, Nissen Fundoplication or narrowing of any portion of the digestive tract. Examples of these GI surgeries include, but are not limited to, gastric banding; however, uncomplicated appendectomies are acceptable. In addition, known history of any surgeries that may have resulted in anatomical GI tract abnormalities such intestinal adhesions, or any other condition that may inhibit passage through any portion of the GI tract must be excluded

18. Subjects with Type 1 diabetes or type 2 diabetes

19. Experienced a myocardial infarction, has a known history of angina, underwent coronary bypass, a known history of congestive heart failure, or is currently being medically treated for any other cardiac condition

20. Poorly controlled hypertension (≥ 160 mmHg systolic and ≥ 100mmHg diastolic)

21. End stage renal disease or requiring hemodialysis within the past 6 months

22. Subjects taking medications on specified hourly intervals that may be affected by changes to gastric emptying, such as anti-seizure or anti-arrhythmic medications

23. Subjects requiring the use of anti-platelet drugs (except for low dose Aspirin as mentioned above) or other agents affecting the normal clotting of blood

24. Study subjects must not have a history of substance use disorder (licit or illicit) drug or alcohol abuse/addiction within 5 years of visit #1 (i.e. day of signing the informed consent document).

25. Study subjects must not have a medical history of sensitivity, intolerance, or toxicity to the investigational product, or agents similar to the investigational product.

26. Study subjects must not have a history of anaphylaxis or anaphylactoid reaction to any prior drug or supplement of any kind.

27. Study subjects must not have a history of cancer with the exception of non-melanoma skin cancer and "in situ" cancer of the cervix.

28. Study subjects must not be anticipating a significant change in job, job duties, or job work hours, which might impair their ability and willingness to undergo study-related procedures under the timelines specified by protocol, and otherwise impede their completion of the study.

29. Study subjects must not anticipate a reasonable likelihood of moving away from the research site, wherein such a move might impair their ability and willingness to undergo study-related procedures within the timelines specified by protocol, or otherwise impede their completion of the study.

30. Subjects who stopped smoking within 6 months prior to Screening Visit or considering smoking cessation during the study

31. Subjects who are habitual laxative users or using prescription medication for chronic constipation

32. Study subjects must not have change in medications treating hypertension and/or dyslipidemia within 1 month prior to Screening Visit (including change in dose)

33. Life expectancy less than 1 year or severe renal, hepatic, pulmonary or other medical condition.

34. Subject is employed by the investigator, or is a close relative of the investigator, or the investigator's staff

35. Subject is a close relative of another subject already enrolled in the study or lives in the same home with another subject enrolled in the study.

36. Subjects on psychiatric medications with no lifetime history of suicidal behavior.

37. Any other condition that, in the opinion of the investigator, would interfere with subject participation, may confound the study results, or interfere with compliance with the study (e.g., psycho-social issues).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Epitomee medical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yael Kenan, Dr

Role: STUDY_DIRECTOR

Epitomee Medical, VP Clinical Affairs

Locations

University of Alabama, Dept of Nutrition Sciences

Birmingham, Alabama, United States

Northwestern University - 645 N. Michigan Avenue, Suite 530

Chicago, Illinois, United States

The University of Kansas, Department of Internal Medicine

Kansas City, Kansas, United States

L-MARC Research Center

Louisville, Kentucky, United States

Pennington Biomedical Research Center , 6400 Perkins Road

Baton Rouge, Louisiana, United States

Wake Forest School of Medicine, Wake Forest Baptist Health - 525 Vine Street, 5th Floor, Suite 5119

Winston-Salem, North Carolina, United States

Center for Weight and Eating Disorders at Perelman School of Medicine University of Pennsylvania - 3400 Civic Center Boulevard, Building 421,

Philadelphia, Pennsylvania, United States

Medical University of South Carolina, Weight Management Center - 67 President Street, Suite 410 South

Charleston, South Carolina, United States

Juno Resreach

Houston, Texas, United States

Countries

United States

References

Bays HE, Ard JD, O'Neil PM, Wadden TA, Kushner RF, Jakicic JM, Wyatt HR, Greenway FL, Kamar M, Ganon-Elazar E, Asaraf LC, Ryan DH. Weight and cardiometabolic effects of a novel oral shape-shifting superabsorbent hydrogel capsule: Prespecified and exploratory analysis of the Epitomee capsule RESET study. Obes Pillars. 2025 Jan 31;13:100163. doi: 10.1016/j.obpill.2025.100163. eCollection 2025 Mar.

Reference Type: DERIVED

PMID: 40028615 (View on PubMed)

Other Identifiers

PRT-05-031

Identifier Type: -

Identifier Source: org_study_id